Your session is about to expire
← Back to Search
Buprenorphine Induction for Opioid Dependence
Study Summary
This trial will help assess if people who are dependent on opioids, specifically fentanyl, will have difficulty being inducted onto buprenorphine. The primary outcome measure is retention on buprenorphine at seven days post induction, with secondary outcome measures of objective precipitated withdrawal and the rate of patients requiring or requesting to initiate methadone due to intolerance of buprenorphine.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 4 trial • 1269 Patients • NCT00315341Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I want to start methadone or naltrexone at the beginning of my treatment.I am willing to start buprenorphine at the beginning of my treatment.I am starting or switching to a maintenance treatment without medication-assisted therapy.I am 18 years old or older.
- Group 1: Micro or Low Dose
- Group 2: Standard Dose
- Group 3: Macro or High Dose
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
May I join this clinical trial?
"Candidates between the age of majority and 99 who suffer from opioid addiction are invited to apply for this clinical trial. 30 individuals in total will be selected as test subjects."
Are the slots for this research endeavor still accessible to participants?
"Patients looking to volunteer for this medical experiment can find relevant information on clinicaltrials.gov; the trial was initially published on May 9th 2022 and last revised on December 1st 2022."
Does this experiment offer participation for individuals over the age of fifty?
"To qualify for inclusion, participants must meet the age range of 18-99. For patients outside this demographic, there are 26 research projects specifically targeting those under 18 and 286 studies centering on elderly individuals aged 65 and above."
How many people are enrolled in this clinical research?
"Affirmative. As evidenced on the clinicaltrials.gov database, this research trial is currently recruiting patients who were initially posted by May 9th 2022 and last updated on December 1st 2022. A total of 30 participants are required across a single medical centre."
Has Buprenorphine/naloxone been tested in previous clinical investigations?
"At present, there are 56 active Buprenorphine/naloxone trials with 13 of them in the final stage. Of all these studies, most are situated in Gainesville, Florida; however, a total of 236 sites across the USA are offering this drug to patients."
Share this study with friends
Copy Link
Messenger